| Autor: |
Dirk J. Blom, Jiyan Chen, Zuyi Yuan, Joao L. C. Borges, Maria L. Monsalvo, Nan Wang, Andrew W. Hamer, Junbo Ge |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Endocrinology, Diabetes & Metabolism, Vol 3, Iss 2, Pp n/a-n/a (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2398-9238 |
| DOI: |
10.1002/edm2.123 |
| Popis: |
Abstract Aims We assessed the change from baseline in vitamin E, steroid hormones, adrenocorticotropic hormone (ACTH), and gonadotropins, overall and by lowest achieved low‐density lipoprotein‐cholesterol (LDL‐C) level, in patients with type 2 diabetes and dyslipidaemia after 12 weeks of treatment with evolocumab. Materials and Methods This was a prespecified analysis of vitamin E, cortisol, ACTH, gonadal hormones and gonadotropins in the 12‐week, placebo‐controlled BERSON trial of evolocumab in patients with type 2 diabetes and dyslipidaemia. In BERSON, 981 (451 in China) patients on daily atorvastatin 20 mg were randomized to placebo or one of two doses of evolocumab. We measured analyte levels at baseline and week 12 (vitamin E in all patients; steroid/gonadal hormones only in Chinese patients). Results In both the global and Chinese populations, absolute vitamin E levels decreased from baseline to week 12 by approximately 6 μmol/L (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text